LPL Financial LLC Purchases 2,795 Shares of Mesoblast Limited (NASDAQ:MESO)

LPL Financial LLC grew its stake in Mesoblast Limited (NASDAQ:MESO) by 7.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,882 shares of the company’s stock after buying an additional 2,795 shares during the period. LPL Financial LLC’s holdings in Mesoblast were worth $770,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its stake in shares of Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares during the period. GAMMA Investing LLC boosted its holdings in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after acquiring an additional 1,213 shares in the last quarter. Ballentine Partners LLC bought a new position in shares of Mesoblast during the fourth quarter valued at $222,000. R Squared Ltd purchased a new stake in Mesoblast during the 4th quarter valued at about $30,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Mesoblast during the fourth quarter valued at approximately $134,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Stock Up 5.6 %

Shares of NASDAQ MESO opened at $10.86 on Wednesday. Mesoblast Limited has a 12-month low of $5.78 and a 12-month high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a 50 day moving average of $13.31 and a 200 day moving average of $13.58.

Analyst Upgrades and Downgrades

MESO has been the topic of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Cantor Fitzgerald upgraded shares of Mesoblast to a “strong-buy” rating in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.